CHICAGO — The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) yielded high response rates with good durability in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the phase 1/2 CADENZA trial. “We conclude that PVEK represents a potentially practice-changing paradigm for patients with the rare disease BPDCN,” said study author Naveen Pemmaraju…
Leave a Comment Leave a Comment
